Health Now
Live

Alzheimer's disease

Alzheimer's disease (AD) is a neurodegenerative disease and is the most common cause of dementia, accounting for around 60–70% of cases. The most common early symptom is difficulty in remembering recent events. As the disease advances, symptoms can include problems with language, disorientation, mood swings, loss of motivation, self-neglect, and behavioral issues. As a person's condition declines, they often withdraw from family and society. Gradually, bodily functions are lost, ultimately leading to death. The median life expectancy following diagnosis of dementia is three to twelve years. Co-occurring movement disorder, also known as extrapyramidal signs, multiplies risk of death by 1.6.

Read more on Wikipedia →

621trials recruiting now
United Statesmost trial sites (283)
400+mapped site locations
Eli Lilly and Companymost active sponsor

Trials by phase

  • Early phase 19
  • Phase 151
  • Phase 288
  • Phase 343
  • Phase 410
  • Not applicable (device/behavioral)243
  • Observational study203

Phase 1 tests safety, phase 2 tests whether it works, phase 3 compares it with standard care, phase 4 follows it after approval.

Countries with the most trials

  • United States283
  • China103
  • France69
  • Canada49
  • Italy46
  • United Kingdom37
  • Spain35
  • South Korea29

Where trials are recruiting

Each dot is a site city; bigger dots have more recruiting trials. Showing up to 400 locations.

Lead sponsors

Eli Lilly and Company · 11Xuanwu Hospital, Beijing · 11Johns Hopkins University · 8Washington University School of Medicine · 8Assistance Publique - Hôpitaux de Paris · 8Bristol-Myers Squibb · 7Indiana University · 7Massachusetts General Hospital · 7

Newest recruiting trials

See all 621 on ClinicalTrials.gov →

General information only, not medical advice. Trial listings are written by sponsors; eligibility and contacts are on each official listing.